August 31, 2018
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Aerie posts $55 million quarterly loss
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Aerie Pharmaceuticals reported a net loss of $55 million, or $1.40 per share, in the second quarter of 2018, compared to a net loss of $28.4 million, or $0.82 per share, in the same period of 2017.
Total costs and expenses for the quarter totaled $58.1 million, compared to $27.8 million in 2017, while research and development costs rose from $10.6 million in 2017 to $18.2 million this year.
Selling, general and administrative costs increased from $17.2 million to $39.9 million.
The higher costs were attributed to increased activities supporting the growth of operations and commercialization of Rhopressa, according to a press release.
As of June 30, 2018, the company had $286.1 million in cash and cash equivalents.